earnings
confidence high
sentiment positive
materiality 0.80
Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook
Natera, Inc.
2025-FY EPS reported
-$1.52
revenue$2,306,113,000
- Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.
- Oncology tests Q4: 233,300 total (225,300 clinical MRD), up 55% YoY; record sequential growth of ~22,800 MRD tests.
- Total tests processed Q4: 923,600 (+17% YoY); FY: 3,525,500 (+15%).
- Cash inflows Q4 ~$30M; FY >$100M, driven by operational improvements.